Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dengue vaccine tetravalent - Sanofi

Next Previous
X
Search
Drug Profile

Dengue vaccine tetravalent - Sanofi

Alternative Names: ChimeriVax; ChimeriVax Tetravalent Dengue Vaccine; ChimeriVax-DEN1-4; ChimeriVax-Dengue; CYD dengue vaccine; CYD dengue vaccine - Sanofi; CYD-4444; CYD-5553; CYD-5555; CYD-TDV; CYD-TDV Dengue Vaccine; Dengue fever vaccine - Sanofi; Dengue Tetravalent Vaccine, Live - Sanofi; Dengue vaccine recombinant tetravalent - Sanofi; Dengue virus vaccine - Sanofi; Dengvaxia; Live, attenuated, dengue serotype 1, 2, 3, 4 virus vaccine; Tetravalent CYD 1,2,3,4 dengue; Tetravalent dengue vaccine - Sanofi; TV-CYD

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Acambis; Sanofi Pasteur
  • Developer Sanofi; sanofi pasteur
  • Class Attenuated vaccines; Dengue vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Dengue

Most Recent Events

  • 01 Mar 2022 Dengue vaccine tetravalent is not yet launched for Dengue (In adolescents, In children, Prevention) in American Samoa, Guam, Puerto Rico, US Virgin Islands and USA (SC, Injection) (NDR batch 21)
  • 29 Apr 2020 Sanofi completes the phase II trial in Dengue (In adolescents, In adults, In children, Prevention) in Colombia and Philippines (SC) (NCT02628444)
  • 12 Dec 2019 Sanofi completes a phase III clinical trial in Dengue (In adolescents, In children, Prevention, In adults, Combination therapy) in Philippines (SC) (NCT02992418)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top